<DOC>
	<DOC>NCT02671500</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC) for 12 weeks in treatment-naive and treatment-experienced participants with chronic hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing and able to provide written informed consent HCV RNA ≥ 10^4 IU/mL at screening Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy HCV treatmentnaive (HCV genotype 1, 2, 3, 4, 5, 6, or indeterminate) or treatmentexperienced (HCV genotype 1, 2, 3, 4, 5, 6, or indeterminate) Liver imaging within 6 months of Day 1 is required in cirrhotic patients only to exclude hepatocellular carcinoma (HCC) Current or prior history of clinicallysignificant illness (other than HCV), gastrointestinal disorder, clinical hepatic decompensation, or postoperative condition that could interfere with the absorption of the study drug Pregnant or nursing female or male with pregnant female partner Chronic liver disease of a non HCV etiology Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>